ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Dr Josep Tabernero speaks with ecancer about the mission and history of the WIN consortium.
He focusses on the challenges surrounding the implementation of precision oncology on a global level, and what innovative solutions the WIN consortium is taking to achieve this.
He also outlines the future for the WIN consortium, and why the WIN Symposium 2019 will be an important meeting to attend.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
The advantages of IORT for early breast cancer treatment
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Moving to the future: Artificial intelligence in surgery